Our findings support the idea that HCT should remain an integral part of cancer treatment during the COVID-19 pandemic but also highlight the need to prioritise preventative measures in those patients who are at increased risk of adverse COVID-19 outcomes. Subgroup analysis showed higher death rates in patients who developed COVID-19 within 12 months of HCT (risk ratio 1.82, 95% CI 1.09–3.03), within 6 months of receiving immunosuppressant drugs (RR 2.11, 95% CI 1.38–3.20) or in the context of active graft-versus-host disease (RR 2.38, 95% CI 1.10–5.16). The cumulative COVID-19-related death rate among HCT recipients was 21% (95% confidence interval 18%–24%), while MV and ITU admission rates were 14% (95% CI 11%–17%) and 18% (95% CI 14%–22%), respectively. Secondary outcomes were COVID-19-related mechanical ventilation (MV) and intensive care unit (ITU) admission. The primary outcome was COVID-19-related death. All studies with at least five patients who reported COVID-19-related deaths in HCT recipients were included. We performed a meta-analysis to address this knowledge gap. They can then recover from their treatment at home.Up-to-date information on coronavirus disease 2019 (COVID-19) outcomes and risk factors in haematopoietic cell transplantation (HCT) recipients is required to inform on decisions about cancer treatment and COVID-19 mitigation strategies. Most patients are discharged within a week of their blood counts recovering. These stem cells end up in the bone marrow and start producing new blood cells. This involves the infusion of the freshly collected donated cells into your bloodstream. This ensures your body’s defences do not attack and reject the donor cells after they are transplanted. Firstly, it reduces the number of cancer cells in your body, and secondly, it suppresses your immune system.
There are two reasons we give you this treatment. The chemotherapy doses can vary between moderate to high dose treatment. After 3-4 days, when the stem cell concentration in the blood is suitable, their stem cells are collected by the apheresis process.Īt the same time the person receiving the donation is given chemotherapy, occasionally in combination with radiotherapy.
Your donor receives the same G-CSF injections that a person receiving an autologous stem cell transplant receives. This involves two processes which occur at the same time. It is only after identifying an available and suitable donor that the final decision about the transplant is made by you and your specialist. The second step is to start a search for a donor. Your decision about this transplant will come only after multiple detailed discussions with your transplant specialist to ensure this is the best decision for you. This is often a complex decision which is dependent on your age and general health and whether this type of transplant is the best treatment for you. The first step in an allogeneic stem cell transplant is determining if the transplant is needed and the risks justified. The processes of an allogeneic stem cell transplant The first step
0 kommentar(er)
